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ABSTRACT 25 
Escherichia coli associated with urinary tract infections and bacteremia have been intensively 26 
investigated, including recent work focusing on the virulent, globally disseminated, multi-27 
drug resistant lineage ST131. To contextualise ST131 within the broader E. coli population 28 
associated with disease, we used genomics to analyse a systematic 11-year hospital-based 29 
survey of E. coli associated with bacteremia using isolates collected from across England by 30 
the British Society for Antimicrobial Chemotherapy, and from the Cambridge University 31 
Hospitals NHS Foundation Trust. Population dynamics analysis of the most successful 32 
lineages identified the emergence of ST131 and ST69 and their establishment as two of the 33 
five most common lineages along with ST73, ST95 and ST12. The most frequently identified 34 
lineage was ST73. Compared to ST131, ST73 was susceptible to most antibiotics, indicating 35 
that multi-drug resistance was not the dominant reason for prevalence of E. coli lineages in 36 
this population. Temporal phylogenetic analysis of the emergence of ST69 and ST131 37 
identified differences in the dynamics of emergence, and showed that expansion of ST131 in 38 
this population was not driven by sequential emergence of increasingly resistant sub-clades. 39 
We showed that over time, the E. coli population was only transiently disturbed by the 40 
introduction of new lineages before a new equilibrium was rapidly achieved. Together, these 41 
findings suggest that the frequency of E. coli lineages in invasive disease is driven by 42 
negative frequency-dependant selection occurring outside of the hospital, most probably in 43 
the commensal niche, and that drug resistance is not a primary determinant of success in this 44 
niche. 45 
  46 
 3 
INTRODUCTION 47 
Escherichia coli is a common commensal of the gastrointestinal tract of humans and other 48 
vertebrates and can be isolated from soil and water. E. coli is also the leading cause of 49 
bloodstream infection in England, elsewhere in Europe and the United States (US) 50 
(Elixhauser et al. 2011; de Kraker et al. 2013; Gerver et al. 2015). Annual rates increased in 51 
England by 80% between 2003 and 2011 (from 16,542 to 29,777), which led to the 52 
introduction of mandatory surveillance from 2011. This documented a 10% increase between 53 
2012/13 and 2014/15, from 32,309 to 35,676 cases (Gerver et al. 2015). The most common 54 
underlying causes for bloodstream infection in a national collection of the British Society for 55 
Antimicrobial Chemotherapy (BSAC) bacteremia resistance surveillance program during 56 
2001–2010 related to urinary tract infection (UTI), gastrointestinal and hepatobiliary 57 
infections (Day et al. 2016). 58 
 59 
Previous genetic studies of E. coli lineages associated with UTI and/or bacteremia in England 60 
and the US have reported that the most prevalent multilocus sequence types (MLST) are 61 
sequence types (ST) ST73, ST131, ST95 and ST69 (Gibreel et al. 2012; Adams-Sapper et al. 62 
2013; Alhashash et al. 2013; Banerjee et al. 2013; Horner et al. 2014). ST131 has received 63 
particular attention following its apparent emergence in the 2000s due to its rapid global 64 
dissemination and frequent multi-drug resistant (MDR) phenotype (Nicolas-Chanoine et al. 65 
2014). This has led to ST131 being well characterised by publications that propose biological 66 
explanations for its emergence and spread (Price et al. 2013; Petty et al. 2014; Salipante et al. 67 
2015; Ben Zakour et al. 2016; Stoesser et al. 2016). Other common STs are less well 68 
characterized despite their association with disease, in part because they are less often 69 
defined as MDR, and because ST131 is an important player in the broader global problem of 70 
increasing antibiotic resistance in Gram-negative bacteria, with clinical isolates that are 71 
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resistant to aminoglycosides, fluoroquinolones, extended-spectrum β -lactamases, 72 
carbapenems and colistin beginning to emerge (Chen et al. 2014; Zhang et al. 2014; Liu et al. 73 
2016; Skov and Monnet 2016). 74 
 75 
Many of the published whole genome sequencing (WGS) studies on E. coli have largely 76 
concentrated on ST131, with fewer focused on other extra-intestinal pathogenic E. coli 77 
(ExPEC). Studies have characterised ST131 in detail and highlighted genetic events leading 78 
to the success of this lineage. Two studies investigating the origin of enteropathogenic E. coli 79 
(EPEC) and atypical enteropathogenic E. coli (aEPEC) and the association of genetic factors 80 
with clinical disease severity illustrated the power of WGS by showing that aEPEC and 81 
EPEC emerged several times in different lineages (Hazen et al. 2016; Ingle et al. 2016), and a 82 
further study analysed a global collection of 362 enterotoxigenic E. coli (ETEC) (von 83 
Mentzer et al. 2014). Smaller studies of local epidemics have concentrated on other 84 
pathotypes and single STs. 85 
 86 
Here, we used WGS to analyse the genetic diversity of a large collection of E. coli isolates 87 
associated with bloodstream infection over more than a decade, using nested systematic 88 
surveys of England and the Cambridge area. These were not selected based on ST or other 89 
bacterial characteristic. We investigated trends in population structure and mechanisms of 90 
antibiotic resistance and captured the introduction of ST131 and ST69, which enabled us to 91 
study the dynamics of emergence and its effect on the wider E. coli population. 92 
 93 
RESULTS 94 
 5 
Study design and bacterial isolates 95 
We conducted a retrospective study in which we analysed WGS data for 1509 E. coli isolates 96 
drawn from national BSAC (n=1094) and local (n=415) collections. The BSAC collection 97 
consisted of isolates submitted to a bacteremia resistance surveillance program 98 
(www.bsacsurv.org) between 2001-2011 by 11 hospitals across England. From each hospital, 99 
the first ten isolates (when available) for each year were included into the study. The local 100 
collection was sourced from the diagnostic laboratory at the Cambridge University Hospitals 101 
NHS Foundation Trust (CUH), Cambridge. Using the laboratory database, we selected every 102 
third isolate associated with bacteremia that had been stored in the -80°C freezer archive 103 
between 2006 and 2012. 104 
 105 
Phylogeny and pan-genome  106 
The 1509 E. coli isolates were resolved into 228 STs. The most frequent STs were ST73 107 
(17.3%), ST131 (14.4%), ST95 (10.6%), ST69 (5.5%) and ST12 (4.6%), which accounted for 108 
more than half of the collection. The distribution of STs between the BSAC and CUH 109 
collections was comparable. Details of all STs are provided in Supplemental Table S1. The 110 
population structure of the collection based on core genome single nucleotide polymorphisms 111 
(SNPs) was defined using Bayesian Analysis of Population Structure (BAPS), which 112 
provides an independent method of assessing the population structure based on the data in the 113 
collection, not based on previous definitions. This correlated well with ST (Figure 1), and we 114 
therefore used STs to allow for direct comparisons between our data and previous studies. 115 
However, there were inconsistencies with phylogroups, which have been linked to the source 116 
of isolation and virulence (Picard et al. 1999), and have been previously used to describe the 117 
E. coli population structure (Lecointre et al. 1998). Most isolates (n=1018, 67%) were assigned 118 
to phylogroup B2. The remainder were distributed between phylogroups F (n=151, 10%), A 119 
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(n=130, 9%), D (139, 9%), B1 (n=69, 5%), and E (n=2, <1%) (Figure 1). Four of the five 120 
most common STs resided in phylogroup B2 (ST73, ST131, ST95 and ST12), while ST69 121 
belonged to phylogroup D. A comparison of ST, BAPS clusters, phylogroup and a maximum 122 
likelihood (ML) tree based on core genome SNPs is shown in Figure 1. The phylogeny 123 
showed five large clades, which generally correspond to phylogroups. However, comparison 124 
between phylogroup and core genome-based phylogeny showed that phylogroups F and D 125 
were mixed rather than monophyletic groups (Figure 1). This is consistent with the PCR data 126 
from Clermont et al. (2013), as well as the presence of an A genotype within the B1 group 127 
(Clermont et al. 2013). The ML tree was dominated by phylogroup B2, which showed large 128 
clonal expansions. These were mostly absent from groups A and B1, which were in turn 129 
dominated by isolates on long branches. 130 
 131 
 7 
 132 
Figure 1. Maximum-likelihood core genome phylogeny of E. coli associated with bacteremia 133 
in England. The columns on the right show, from left to right, phylogroup, STs containing 134 
more than ten isolates, and hierBAPS clusters. Phylogroups are also presented by background 135 
shading and STs labelled on the right. Black represents ST designation not shown due to 136 
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these having less than ten isolates. The root has been placed according to previous 137 
understanding of Enterobacteriaceae phylogeny.  138 
 139 
Analysis of the pan-genome demonstrated an open pan-genome containing 69,274 genes and 140 
no sign of reaching a plateau (Supplemental Figure S1). Using a strict definition of core 141 
genome, only 885 genes were present in all 1509 isolates although this rose to 1744 genes 142 
using a cut-off of presence in 99% of isolates. The vast majority of genes (62,753 of 69,274, 143 
91%) were present in less than 15% of the isolates. 144 
  145 
The population structure of E. coli associated with bacteremia 146 
Two STs appeared in the collection for the first time during the timeframe of the study, with 147 
ST69 first detected in 2002 and ST131 in 2003. The proportion of STs in each year of the 148 
collection is shown in Figure 2. Within a short period after the emergence and spread of ST69 149 
and ST131 the population established a new equilibrium, whereby the proportion of the 150 
major STs remain relatively unchanged. The proportion of ST73, ST95 and ST12 before and 151 
after the emergence of ST131 were on average 24% versus 17%, 8% versus 11%, and 7% 152 
versus 4%, respectively. The proportion of the remaining STs fell from 59% before the 153 
emergence of ST131 to 42% after, but was stable from then until the end of the sampling 154 
period.  155 
 156 
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 157 
Figure 2. Proportions of STs during the 11 year sampling framework. The percentage of each 158 
ST has been plotted by year ordered by the frequency at the start of the study (most common 159 
at the bottom). The emergence of ST131 and ST69 can be observed in 2003 and 2002, 160 
respectively. 161 
 162 
Genetic characterisation of ST131 163 
Three major clades have been identified for ST131 (Price et al. 2013; Petty et al. 2014): clade 164 
A corresponds to serotype O16:H5, clade B is serotype O25:H4 and is negative for the 165 
fimH30 allele, and clade C (H30) is serotype O25:H4 and positive for fimH30 and sub-166 
divided by the acquisition of fluoroquinolone resistance in clade C1 (H30-R in Price et al). 167 
This has been further divided into clade C2 (H30-Rx in Price et al), described previously as 168 
having acquired blaCTX-M-15 encoding extended spectrum beta-lactamase, followed by 169 
expansion of this clade (Price et al. 2013; Olesen et al. 2014). Our 218 ST131 isolates were 170 
assigned to these lineages using previously-described lineage-defining variation. This 171 
demonstrated that 197 (90%) were serotype O25:H4, and 18 (9%) isolates at the base of the 172 
lineage were serotype O16:H5 and fimH41. For two isolates the serotype could not be 173 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
ST73
ST95
ST12
ST10
ST144
ST131
ST69
 10 
explicitly defined in silico and one was defined as O18ac:H4. One O25:H4 isolate was within 174 
the O16:H5 positive clade A. The C1 clade was defined based on a comparative phylogenetic 175 
analysis with the Price et al. 2013 isolates (Supplemental Figure S2) and in silico PCR to 176 
detect H30-Rx (C2) specific SNPs. Of the 161 ST131 isolates in lineage C, 129 belonged to 177 
the C2 clade (Figure 3). The assignment of isolates to clades was confirmed by investigating 178 
six previously reported clade specific SNPs for B, C, C1 and C2 (Ben Zakour et al. 2016). 179 
This confirmed our assignment of isolates to clades and revealed that the three fimH27 180 
isolates in the B clade most likely belong to the B0 clade defined by Ben Zakour et al. 181 
(2016). 182 
 183 
 11 
 184 
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Figure 3. ST131 maximum-likelihood phylogenetic tree based on SNPs called against the 185 
reference EC958. Columns to the right of the tree show the in silico predicted serotype (O16-186 
H5 or O25-H4), phenotypic resistance to ciprofloxacin (CIP res.), SNP based definition of 187 
fimH, gyrA and parC genotypes and the presence of blaCTX-M and the type. NA:H4 in the 188 
serotype indicates that we were unable to assign a definite O type for the isolate. It has not 189 
been counted as a new serotype. Clades assigned based on the markers and clade specific 190 
SNPs are shown on the right. The only isolate with missing data (black) is the reference strain 191 
EC958. The tree is mid-point rooted. 192 
 193 
 194 
We then mapped blaCTX-M-15 and fluoroquinolone resistance across the ST131 collection. 195 
blaCTX-M-15 was present in both C1 and C2 clades, but was not detected in clades A or B 196 
(Figure 3). A parsimony reconstruction of the presence of blaCTX-M-15 within a EC958 197 
reference genome-based ML phylogeny using both acctran and deltran methods indicated at 198 
least 28 introductions and/or losses of the blaCTX-M-15 gene in this data set. This indicates that 199 
blaCTX-M-15 has been acquired and lost repeatedly in the C1 and C2 clades (Supplemental 200 
Figure S3). The majority of the fimH30 positive C isolates were ciprofloxacin 201 
(fluoroquinolone) resistant, with a small number of exceptions. A cluster of eight 202 
fluoroquinolone-susceptible isolates resided close to the root of the C clade, together with 203 
two sporadic isolates in the C1 clade. Altogether, 75 of ST131 isolates were blaCTX-M-15 204 
positive. The C1 clade contained only 23 isolates but of these, two were blaCTX-M-15 positive 205 
and another four had acquired blaCTX-M-27. Of the 129 clade C2 isolates 73 were blaCTX-M-15 206 
positive. Isolates in lineage A and B were mostly susceptible to ciprofloxacin, the exceptions 207 
being one isolate in clade A that was resistant to ciprofloxacin and two clade A isolates with 208 
intermediate resistance. The resistant isolate had the gyrA mutation associated with 209 
fluoroquinolone resistance (gyrA1AB) (Johnson et al. 2013). 210 
 211 
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ST131 espC island 212 
We analysed the presence of 3511 virulence genes in the whole collection and observed that 213 
just one gene was almost specific to the ST131. This was present in ST131 and the closest 214 
lineages in the B2 phylogroup. This was more common in ST131 (N=216, 99.08%) 215 
compared with other STs (p-value<2.2e-16) The gene was annotated as espC (a member of 216 
the Serine Protease Autotransporters of Enterobactericeae, SPATE, family). The gene is 217 
contained in a genetic island reported previously as ROD3 in ST131 strain EC958 (Totsika et 218 
al. 2011), but is not identical to the first description of an espC pathogenicity island which 219 
was originally reported in EPEC (Stein et al. 1996; Mellies et al. 2001; Schmidt and Hensel 220 
2004). The sequence identity/similarity of the EPEC espC and EC958 espC was 68% for 221 
DNA and 69/73% for protein. The ST131 espC island has genes coding for fimD, focC 222 
(fimC), tsh, cfaD (regA), and espC, along with two poorly characterised proteins, one with 223 
similarity to fimbrial adhesins and one to DNA binding proteins. The island is bordered by 224 
yjdJ genes. The locus where the island is inserted is conserved at the yjdIJKO gene region, 225 
between the dcuS and lysU genes in E. coli reference strain K-12 MG1655 (NC_000913.2). 226 
Analysis of mapping coverage to the reference EC958 showed that the island was present in 227 
all ST131 isolates (N=218), closely related clades to ST131 in the B2 phylogeny (N=45) and 228 
four isolates in phylogroup D and six in phylogroups B1/A. A region of the island is missing 229 
from 11% of the ST131 isolates, 19 of which belong to the clade A and were missing a 230 
common region. The same region was missing in the clades close to ST131 in the phylogeny 231 
(Supplemental Figure S4). The espC allele present outside of the ST131 clades B and C was 232 
often different than the espC in the rest of ST131 (Supplemental Figure S5). 233 
 234 
ST73 and ST131 have different strategies to achieve prevalence 235 
ST73 and ST131 represented the predominant STs in the collection, but are known to have 236 
contrasting antibiotic resistance profiles. Consistent with this, our ST131 isolates were 237 
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predominantly MDR and ST73 was largely susceptible (Figure 4 and Supplemental Figure 238 
S6). This was reflected by the presence of numerous antibiotic resistance genes in ST131 239 
compared with ST73, which was accounted for at least in part by different plasmid profiles. 240 
ST131 was the main lineage in the collection to carry an incFIA plasmid(s) (Figure 4 and 241 
Supplemental Figure S6). This contained aac6’-lb-cr, blaCTX-M-15 and blaOXA1 and indicates 242 
that this plasmid is mostly responsible for the multi-drug resistant ST131 phenotype 243 
(Supplemental Figure S6). A more widely disseminated plasmid in ST131 was also present 244 
and carried incFIB often in addition to incFIA. This plasmid encodes blaTEM-1, dfrA, mphA, 245 
sul1 and tetA. Due to the limitations of Illumina short-read technology, it is not possible to 246 
further delineate the structure of the genetic element encoding these genes and therefore the 247 
presence of genes in specific plasmids is determined by association alone and has a level of 248 
uncertainty. The difference in susceptibility profiles of ST73 and ST131, which remain at 249 
stable proportions of the population throughout the study after the introduction of ST131, 250 
suggests that resistance may not be the primary determinant of successful establishment and 251 
maintenance in the reservoir niche.  252 
 253 
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 254 
Figure 4. Multi-drug resistance plasmids present in ST131. Phylogeny of the whole collection 255 
with columns to the right representing phylogroup, five most frequent STs, phenotypic 256 
antibiotic resistance data linked to the plasmid (ceftazidime, ciprofloxacin, cefotaxime, 257 
cefuroxime and gentamicin), the presence of incFIA and incFIB as well as antibiotic 258 
resistance genes carried by the plasmid (aac(6')-Ib, blaCTX-M, blaOXA, dfrA, mphA, sul1 and 259 
tetA), black=missing, colour=present. The phylogenetic tree is the same as in Figure 1. 260 
 261 
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 262 
Comparing the phylogeny of the two lineages showed that ST131 was mainly dominated by 263 
clade C isolates, which were very closely related, but the ST73 tree has several more 264 
divergent clades. The average pairwise SNP distance between all the ST131 isolates was 156 265 
SNPs (median=74 SNPs) (Figure 3). By contrast, the ST73 phylogeny comprised at least 8 266 
clades with isolates that were much less closely related (average pairwise SNP distance in 267 
ST73 is 335 SNPs, median=332 SNPs) (Figure 5). This is underlined by the observation that 268 
ST73 isolates were assigned to 9 serotypes in silico, and the different serotypes were in 269 
phylogenetically separate lineages. It seems likely that a change in serotype has occurred at 270 
least 7 times in ST73 (Figure 5). By contrast, within ST131 only three serotypes were 271 
identified. O16:H5 was present in clade A and O25:H4 present in the rest of the phylogeny 272 
represented by clades B and C. One isolate in the C2 clade was O18ac:H4. A comparison of 273 
the presence of virulence genes in ST73 and ST131 revealed differences in the presence of 274 
the UPEC/ExPEC virulence genes between the two (Supplemental Figure S5), suggesting 275 
that again, there is not a single configuration that is best for success in this niche represented 276 
by MDR ST131, but rather also susceptible, but fit and virulent, STs can become prevalent. 277 
For example, most ST131 isolates lacked gene clusters hlyABCD (hemolysin) and iroBCDN 278 
(salmochelin) but carried genes for aerobactin (iucABCD, iutA), hemin uptake 279 
(chuASTUWXY;), and yersiniabactin (fyuA, irp1, irp2, ybtAEPQSTUX) (Supplemental Figure 280 
S7). It seems that ST131 can use only aerobactin, yersiniobactin and the chuASTUWXY for 281 
iron acquisition, but for example ST73 has the potential to use all these and others. 282 
 283 
An interesting similarity between the two most prevalent lineages ST131 and ST73 is that 284 
both are positive for sat (ST131 89% and ST73 87%), a gene encoding a secreted 285 
autotransporter toxin that is toxic for kidney and bladder cell lines (Guyer et al. 2000) and is 286 
less widely present in rest of the population (27%) (p-values < 2.2e-16). Another similarity is 287 
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the absence of aec genes in ST73 and ST131 (except aec7 which is present in ST73), which 288 
encode genes associated with type 6 secretion, although they were widely present in the rest 289 
of the phylogeny (Supplemental Figure S5). 290 
 291 
 292 
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Figure 5. ST73 maximum-likelihood phylogenetic tree based on SNPs called against the 293 
reference CFT073. The in silico predicted serotype is shown to the right of the tree. For 294 
serotype NA:H1 the O type could no be assigned. This is not counted as a new serotype. The 295 
clades are labelled on the right. The tree is mid-point rooted. 296 
 297 
 298 
Two strategies for emergence – ST131 and ST69 299 
Two independent lineages (ST69 and ST131) became established in our study population 300 
during the study period. To investigate the structure and history of this emergence we 301 
constructed temporally resolved phylogenies using Bayesian evolutionary analysis by 302 
sampling trees (BEAST). Based on the BEAST analysis the MRCA (most recent common 303 
ancestor) for ST69 was dated to 1956 (95% highest posterior density (HPD) interval, 1935–304 
1971). This separated the major clade in the ST69 tree that subsequently divided into two 305 
large lineages in 1977 (95% HPD interval, 1965–1986) (Supplemental Figure S8). Using the 306 
Bayesian skyline model we could estimate the effective population size in the past. The 307 
analysis showed three increases in the population size. The first increase beginning in the late 308 
1970s and the second in the 1990s were smaller than the last rapid increase that occurred 309 
relatively close to the year 2000 (Supplemental Figure S9). If the confidence interval is taken 310 
into account, we hypothesise that we observed the last increase in population size during this 311 
study. 312 
 313 
The BEAST analysis estimated that the MRCA of the clades with the two different serotypes 314 
in ST131 was around 1874 (95% HPD interval, 1697–1951) (Figure 6 and Supplemental 315 
Figure S10). The C clade diverged from the rest of the phylogeny around 1960 (95% HPD 316 
interval, 1899–1985) and the fluoroquinolone resistant C1 clade is estimated to have diverged 317 
from the rest of the ST131 lineages around 1982 (95% HPD interval, 1948–1995). We 318 
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repeated this analysis with Least-Squares Dating (LSD) which gave a date for the MRCA of 319 
the complete ST131 collection of 1828 (confidence interval 1672-1891), 1934 (1871-1960) 320 
for divergence of clade C from A and B clades, 1979 (1953-1991) for divergence of the 321 
fluoroquinolone resistant clade from the rest, and 1986 (1965-1993) for the divergence of C2 322 
clade from C1. The majority of the ST131 nodes, including the fluoroquinolone susceptible 323 
lineages in the tree had a divergence time of 30 years or less. This is indicative of the fact that 324 
the whole ST131 lineage, rather than just a single clade within it, has increased in prevalence 325 
after its observed emergence in England in the 2000s. This is also apparent from an analysis 326 
of isolation dates against the phylogeny of ST131 in our collection (Supplemental Figure 327 
S11). It can be seen that nearly all of the major clades of the tree contained isolates from 328 
every year, indicating that the whole population was present in each year throughout the 11 329 
years in this study, not just the clade C2. The skyline plot showed a sharp increase in the 330 
population size around the year 2000 (Supplemental Figure S9). This most likely correlates 331 
with the emergence of the ST131 lineage that we observed in our data set.  332 
 333 
 334 
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Figure 6. Temporal analysis on ST131 using BEAST. Figure shows the serotype, resistance 335 
to Ciprofloxacin (CIP res.), assignment to clade C2 (H30-Rx), and the gene alleles of fimH, 336 
gyrA and parC. * MRCA, ** emergence of clade C, *** emergence of CIP resistant clade 337 
C1.  338 
 339 
Distribution of virulence factors  340 
We analysed the repertoire of virulence factors, focusing on genes present or absent in the 341 
most prevalent sequence types in our collection, ST73 and ST131. ST131 is known to cause 342 
urinary tract infections, yet this clade has only a partial pap (P fimbriae or pyelonephritis 343 
associated pilus) gene operon (Clark et al. 2012): 82% of ST131 had only papABIX or fewer 344 
genes from the operon and not e.g. the tip adhesin papG. In more detail, 90% of ST131 345 
isolates had papA, but only 17% had the tip adhesion papG (Supplemental Figure S7). Most 346 
of the other clades in the B2 phylogroup contained the intact operon, which was also present 347 
in other phylogroups. In addition, the most closely related clades to ST131 were also missing 348 
most of this operon. Genes encoding enterotoxins set1AB, autotransporter pic, F1C fimbrial 349 
genes focAGH, and the autotransporter upaH (Supplemental Figure S5) were found in ST73 350 
but were rare in other STs. 351 
 352 
Mapping against the reference strain EC958 also enabled us to analyse the presence of the 353 
reported ST131 genomic island ROD3 (Totsika et al. 2011) and the type 6 secretion system 354 
(T6SS) across the whole invasive E. coli population in England (Supplemental Figure S4). 355 
T6SS was specific to the B2 phylogroup. The T6SS is used as an anti-competition 356 
mechanism to enhance survival in a competitive niche such as the gut (Chatzidaki-Livanis et 357 
al. 2016; Sana et al. 2016). This may be one explanation for the prevalence of the B2 358 
phylogroup in our collection. 359 
 360 
 21 
Antibiotic resistance 361 
Phenotypic antibiotic resistance to ciprofloxacin increased from 10.5% to 28.8% (probably 362 
due to the emergence of ST131) and peaked in 2006, but remained under 20% from 2008–363 
2012. It is striking that there was no consistent change in the phenotypic antibiotic resistance 364 
of the two most prevalent sequence types, ST73 and ST131, except for ampicillin resistance 365 
in ST73 (Figure 8). Furthermore, there was no clear increase in antibiotic resistance over time 366 
for the whole collection. ST131 was more resistant to most antimicrobials than ST73 (and 367 
often the rest of the collection) and contained the most antibiotic resistance genes (Figure 4). 368 
However, the equally successful ST73 was one of the least resistant lineages to most 369 
antimicrobials. Phenotypic antibiotic susceptibility results are summarised in Table 1. 370 
 22 
 371 
Figure 7. Comparison of antibiotic resistance of ST131, ST73 and the whole collection. 372 
Phenotypic antibiotic resistance data is represented by % of non-susceptible (resistant + 373 
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intermediate) isolates per year. Each subfigure represents one antibiotic class. Carbapenems 374 
(imipemen, meropenem and ertapenem) and tigecycline are not shown due to the lack of 375 
resistance against these classes in this collection. AMK=amikacin, GEN=gentamicin, 376 
TOB=tobramycin, TMP=trimethoprim, CEF=cefalotin, FOX=cefoxitin, CXM=cefuroxime, 377 
FEP=cefepime, CTX=cefotaxime, CAZ=ceftazidime, AMX=amoxicillin, AMP=ampicillin, 378 
CIP=ciprofloxacin, ATM=aztreonam, AMC=amoxicillin-clavulanic acid, TZP=piperacillin-379 
tazobactam. 380 
 381 
DISCUSSION 382 
We analysed whole-genome sequence data for 1509 E. coli blood isolates taken from a 383 
systematic sentinel-based surveillance program across England, as well as unbiased sampling 384 
from a University hospital, isolated in 2001–2012. This eleven-year period enabled us to 385 
analyse the temporal trends in the population structure and changes in the antibiotic 386 
resistance of invasive E. coli as well as characterize in detail the most prevalent sequence 387 
types causing bacteraemia. The most predominant STs were ST73, ST131, ST95, ST69 and 388 
ST12. These belong to E. coli phylogroups B2 and D, which have been previously associated 389 
with virulent and pathogenic UPEC and ExPEC strains (Picard et al. 1999; Johnson and Stell 390 
2000; Johnson et al. 2001). The fact that some of the genotypes from the (in silico) PCR did 391 
not present monophyletic clades made it difficult to assign all isolates to phylogroups without 392 
the use of a phylogenetic tree. The pattern of prevalence of STs is consistent with previous 393 
studies of isolates associated with urinary sepsis or bloodstream infection; for example, 394 
during a similar time period in Ireland the most frequent STs were ST131, ST73 and ST69 395 
(Miajlovic et al. 2016) and the E. coli from the BSAC Bacteraemia Resistance Surveillance 396 
Programme have the same most common profiles (CC73, CC131 and CC95) as this 397 
combined collection from BSAC and CUH (Day et al. 2016). This also shows that the 398 
collections from BSAC and CUH are similar when STs are considered. Information from 399 
hierBAPS clustering showed that BAPS clusters were more often monophyletic than STs 400 
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since single and double locus variants often disturbed the uniformity of ST clades. The 401 
presence of phylogroup F isolates within group D, already reported in the original article 402 
presenting the method (Clermont et al. 2013), made the use of the current PCR-based method 403 
for assigning isolates to phylogroups problematic for some clades. 404 
 405 
The study period captured the emergence of ST69 and ST131 into our study population, but 406 
the introduction of these lineages only disturbed the population structure transiently after 407 
which it quickly reached a new equilibrium, with the new lineages subsequently maintaining 408 
a stable proportion of the population. Despite its apparent success, the globally disseminated 409 
MDR lineage ST131 failed to become dominant in the whole population. The most common 410 
lineage prior to the emergence of ST131, ST73, only reached a proportion of over 20% of the 411 
whole population in a single year. This suggests that the driver for the overall structure of the 412 
population and proportions of successful clones may be a form of negative frequency-413 
dependent selection. New STs have an advantage when rare, but this is lost when they 414 
become more common. One hypothesis to explain this is that the E. coli causing bloodstream 415 
infections do not form a discrete population, but represent a spill-over of E. coli that occupy a 416 
commensal niche in the wider human population. This is supported by evidence that both 417 
drug-resistant (ST131) and drug-susceptible (ST73) lineages are equally successful in being 418 
maintained in this reservoir, and that drug resistance as a whole in the population is not 419 
increasing, demonstrating that antibiotic resistance is not a primary driver of success or 420 
prevalence in this niche. In the case of ST131, this is supported by the findings of Ben 421 
Zakour et al. (2016) who reported that that virulence determinants were acquired before the 422 
emergence of the fluoroquinolone resistant C clade (Ben Zakour et al. 2016). According to 423 
this hypothesis, the primary forces shaping the population are not those within the hospital 424 
environment, but are due to competition within the gut commensal niche in the broader 425 
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human population, where antibiotic use is more sporadic than in the hospital population. This 426 
is a strong contrast with the population structure of true nosocomial pathogens such as 427 
methicillin-resistant Staphylococcus aureus (MRSA), where specific drug-resistant clones 428 
sequentially dominate the population within a niche where antibiotic exposure is common 429 
and drug resistance is a strong selective advantage.  430 
 431 
ST73 in our collection was susceptible to the antibiotics tested, but a recent report from the 432 
UK found several MDR ST73 isolates associated with an MDR plasmid (Alhashash et al. 433 
2016). Further studies are needed to define whether this MDR phenotype will become more 434 
disseminated in ST73 over time. 435 
 436 
Although previously reported to be present in the UK and Ireland from 2001 (Day et al. 437 
2016), we observed the appearance of ST69 and ST131 within our sampling framework. We 438 
used BEAST to analyse their emergence and found that the events leading to their spread 439 
seem quite different. A Bayesian skyline analysis of ST69 showed several sequential minor 440 
increases in population size, which started in the late 1970s with the last and most rapid one 441 
coinciding with the beginning of this study. The most recent common ancestor of ST69 could 442 
be dated to around 60 years ago. A similar analysis of the ST131 lineage identified that the 443 
split between the O25:H4 and O16:H5 lineages occurred around 142 years ago. The 444 
phylogeny and the Bayesian skyline analysis support the observation that there was a single 445 
rapid expansion of this clade in the last few years, starting around 1995. However, rather than 446 
being due to a single sub-lineage, this expansion seems to have happened in the entire 447 
O25:H4 clade and possibly the whole ST. According to our analysis, the fimH30 carrying 448 
clade C diverged from clade B around 1960, the fluoroquinolone resistant clade C1 (H30-R) 449 
diverged from clade C around 1982 and clade C2 (H30-Rx) diverged from the rest of clade C 450 
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around 1990. These dates are somewhat different from the recently published analyses of 451 
Stoesser et al (2016) and Ben Zakour et al (2016). The emergence of the fluoroquinolone 452 
resistant subset of the C clade in the 1980s found here is consistent with two previous 453 
publications. Similarly, the divergence of the C2 clade from the C1 in 1990 reported here is 454 
similar to the year of 1987 reported by Ben Zakour et al. (2016) and Stoesser et al (2016). 455 
This indicates a strong temporal signal in the sequences for these genetic events. The 456 
difference in other dates are most likely due to weaker temporal signals in the data for these 457 
events e.g. the divergence of the C clade from B clade is dated close to the year 1960 by Ben 458 
Zakour et al. (2016) and in this study, but to 1985 by Stoesser et al (2016).  The fact that all 459 
of the ST131 clades were present during the whole study period indicates that the entire 460 
ST131 lineage is successful, and not just clade C or the fluoroquinolone resistant and ESBL-461 
expressing clades C1 and C2. 462 
 463 
For ST131 the presence of blaCTX-M-15 was initially reported to be exclusive to the H30-Rx 464 
(C2) clade (Price et al. 2013). In our collection, blaCTX-M-15 was found in both the C1 and C2 465 
clades. We also identified that blaCTX-M-15 was acquired and/or lost several times in the ST131 466 
population studied here. Stoesser et al. had previously hypothesised that this could occur 467 
based on the diverse contexts in which the gene is found (Stoesser et al. 2016). It is also 468 
noteworthy that our unbiased sample of E. coli causing BSI was dominated by C2 isolates, 469 
with over 80% of clade C isolates and almost 60% of all the isolates belonging to clade C2. 470 
This is in contrast to the previous reports of the ST131 population structure where the C1 and 471 
C2 have been more equally distributed (Price et al. 2013; Petty et al. 2014; Ben Zakour et al. 472 
2016; Stoesser et al. 2016). 473 
 474 
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The pan-genome of our collection of invasive E. coli included almost 70,000 genes. The core 475 
was very small and most of the genes in the pan-genome were present in a small subset of 476 
strains, reflecting the massive diversity of E. coli. Previous reports on the size of the E. coli 477 
pan-genome have been markedly smaller, but also the data sets that the analyses were 478 
performed on have been smaller. With an open pan-genome this will have an effect on the 479 
pan-genome size. Rasko et al. reported a pan-genome of over 13,000 genes and a core of 480 
2,200 genes from an analysis of a diverse set of 17 genomes from different E. coli pathovars 481 
(Rasko et al. 2008). Chen et al. analysed the pan and core-genomes of seven UPEC isolates 482 
and reported a core genome of 2,865 genes (Chen et al. 2006). Both of these estimates of the 483 
core are considerably larger than ours. This may be due to the high similarity cut-off in our 484 
analysis, which will make the core genome appear smaller and the pan-genome larger. 485 
However, even with a cut-off of 90% the pan-genome is 46,022 genes in this dataset and the 486 
core genome 1170 genes. Recently, a core of 1,080 gene clusters was reported in a study 487 
investigating 70 EPEC isolates using large-scale BLAST score ratio analysis (Hazen et al. 488 
2016). This is closer to our number of 885 core genes even though the pan-genome in the 489 
analysis by Hazen et al. was only 12,964 gene clusters. This is likely due to the different 490 
methods that were used in the analyses. 491 
 492 
The proportion of antibiotic resistant isolates in the data set did not increase substantially 493 
during the 11 years that were included in this study. The resistance patterns fluctuated over 494 
time, which was probably due to the relatively small sample size per location per each year. 495 
Despite the fact that we did not observe a clear increase in the proportion of resistance, there 496 
have been many recent reports suggesting an increase in the proportion of resistant isolates 497 
(ESPAUR 2015; Ironmonger et al. 2015). This may be due to differences at the regional 498 
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level, while this study was performed at a nationwide level, and therefore smaller increases at 499 
a local level might not have been apparent.  500 
 501 
The analysis of virulence factors in this diverse population enabled us to compare the most 502 
successful lineages to each other and to the rest of the population. We identified a number of 503 
virulence factors that were differentially present between lineages. One gene, the serine 504 
protease autotransporter (SPATE) espC, was specific to ST131 and closely related lineages. 505 
This is situated in a pathogenicity island that is restricted almost exclusively to ST131 and its 506 
closest clades. This island was first reported by Totsika et al. (2011) as a region of difference 507 
3 (ROD3), and has previously been reported to be present throughout ST131 by Petty et al. 508 
(2013), but not to be conserved in clade A (Totsika et al. 2011; Petty et al. 2014). Since the 509 
ST131 espC island does not have an integrase or other mobility related genes it is not clear if 510 
it is a self- mobile element. Its sporadic acquisition in different branches of the tree could 511 
reflect acquisition by mechanisms other than self-mobility (such as homologous 512 
recombination in flanking sequences) or could potentially represent lineage specific deletion. 513 
In EPECs espC has been shown to play a role in cell death by causing apoptosis and necrosis 514 
(Serapio-Palacios and Navarro-Garcia 2016) and the ST131 espC island has recently been 515 
reported to harbour a gene encoding the regulatory protein RegA (annotated as cfaD by 516 
Prokka in our analysis) that is present in Citrobacter rodentium and Escherichia clades III, 517 
IV and V (Tan et al. 2015). Incorporation of this island may be one reason for the success of 518 
ST131. There were several genes present almost exclusively in ST73 that could in part 519 
contribute to its success. These genes were focAGH (encoding F1C fimbriae genes), pic 520 
(encoding another SPATE gene), set1AB  (encoding Shigella enterotoxin 1) and upaH which 521 
is an autotransporter that induces biofilm formation and bladder colonisation (Allsopp et al. 522 
2010; Allsopp et al. 2012). The secreted autotransporter toxin encoded by sat (another 523 
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SPATE gene) was present in both ST131 and ST73 and could be contributing to the success 524 
of both lineages.  525 
 526 
One limitation of this study is that although the collection was drawn from 11 centres over 11 527 
years, it only comprised the first 10 isolates per site each year except in the case of CUH. It 528 
could therefore potentially include isolates from temporally limited local epidemics, which 529 
could skew the results and interpretation. In addition, the limitation of short-read sequencing 530 
is evident when analysing plasmids. The dynamic nature of plasmids, in combination with 531 
short reads generated by the Illumina HiSeq, means that many differences in plasmid 532 
structure are unlikely to be captured by our analyses. We are also unable to assemble 533 
complete plasmid sequences and so the presence of genes in plasmids with given inc-types is 534 
based on association alone. More detailed analysis would require the use of long read 535 
technologies. Determining the presence of genes by association alone adds a degree of 536 
uncertainty to the results due to untypeable plasmids and the mobile nature of the genetic 537 
elements that can be present in the chromosome. 538 
 539 
In summary, we have analysed the population structure of E. coli associated with 540 
bloodstream infection over an 11-year period in England. During this time we observed the 541 
emergence of ST131 and ST69, but this introduction did not disturb the population structure 542 
for long, and a new equilibrium was quickly established. The globally disseminated MDR 543 
lineage ST131 was not the most frequently identified lineage in this collection; this was 544 
ST73, which is generally susceptible to most antibiotics. This indicates that antibiotic 545 
resistance is not a primary driver of success in the niche occupied by these E. coli. The 546 
relatively static structure of the population suggests that it is instead driven by negative 547 
frequency-dependent selection occurring in the commensal niche in the wider human 548 
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population, and that bacteraemia represents a spill-over from this population. This 549 
emphasises the importance of surveillance of the wider human population to understand the 550 
dynamics and structure of invasive E. coli. 551 
 552 
MATERIALS AND METHODS 553 
Bacterial isolates 554 
A total of 1522 E. coli isolates were initially included in the study. Of these, 1098 were from 555 
the British Society for Antimicrobial Chemotherapy (BSAC) Bacteraemia Resistance 556 
Surveillance Programme (www.bsacsurv.org) (Reynolds et al. 2008) between 2001 and 2011 557 
(Supplemental Table S2). Up to 10 isolates (when available) were obtained for each year 558 
from 11 contributing laboratories distributed across England. The 11 centres were selected in 559 
order to provide geographical and temporal diversity. A further 424 isolates were sourced 560 
from the diagnostic laboratory at the Cambridge University Hospitals NHS Foundation Trust, 561 
Cambridge. Using the laboratory database, we selected every third isolate associated with 562 
bacteraemia that had been stored in the -80°C freezer archive between 2006 and 2012. 563 
Thirteen isolates were subsequently excluded (4 and CUH isolates and 9 BSAC isolates) 564 
based on low quality of sequence data or species misidentification, giving a final sample size 565 
of 1509 isolates. Antimicrobial susceptibility testing was performed using the Vitek2 566 
instrument with the N206 card (Biomerieux, Marcy l’Etoile, France) for isolates from CUH, 567 
and using the agar dilution method for the BSAC collection (Andrews 2001). For the 568 
purposes of this analysis we combined phenotypic antibiotic resistance data from BSAC and 569 
CUH, and grouped together the intermediate and resistant isolates in the analyses to represent 570 
the non-susceptible part of the population. Since the isolates from BSAC and CUH have been 571 
tested against different antibiotic combinations we have antibiotic resistance data from 2001–572 
2011 for amoxicillin and imipenem; from 2006–2012 for amikacin, tobramycin, ampicillin, 573 
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ertapenem, meropenem, aztreoman, cefalotin, cefoxitin, cefepime and trimethoprim and 574 
throughout the study period (2001–2012) for gentamicin, tigecycline, cefuroxime, 575 
ceftazidime, cefotaxime, ciprofloxacin, amoxicillin-clavulanic acid and piperacillin-576 
tazobactam. 577 
 578 
The National Research Ethics Service (ref. 12/EE/0439) and the Cambridge University 579 
Hospitals NHS Foundation Trust (CUH) Research and Development (R&D) Department 580 
approved the study protocol. 581 
 582 
DNA extraction and sequencing 583 
Genomic DNA was extracted using a QIAxtractor (QIAGEN) and library preparation 584 
performed according to the Illumina protocol. Index-tagged libraries were created, 96 isolates 585 
multiplexed per lane and sequenced using the Illumina HiSeq 2000 platform (Illumina Inc.) 586 
to generate 100 base pair (bp) paired-end reads. Average sequencing depth was 77-fold, with 587 
a minimum of 48-fold. 588 
 589 
Sequence data analysis 590 
MLST was performed using an in-house script (https://github.com/sanger-591 
pathogens/mlst_check) and sequence types (ST) defined using the Warwick MLST scheme 592 
(Wirth et al. 2006). De novo assembly was performed using Velvet (Zerbino and Birney 593 
2008), and scaffolds were generated using SSPACE (Boetzer et al. 2011) and GapFiller 594 
(Boetzer and Pirovano 2012). Reads were mapped back to the assemblies using SMALT 595 
(Ponstingl 2013). Assemblies were annotated with an in-house pipeline based on Prokka 596 
(Seemann 2014). Annotated assemblies were used in a pan-genome analysis in Roary, from 597 
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which a core genome alignment was generated (Page et al. 2015). List of genes in the core 598 
genome and the core genome alignment are can be downloaded from Figshare. 599 
 600 
Bayesian analysis of population structure (hierBAPS) (Corander et al. 2008; Cheng et al. 601 
2013) was used to analyse the population structure. A core genome alignment was produced 602 
with Roary and a SNP alignment was generated using SNP-sites (Page et al. 2016) and used 603 
in hierBAPS which was run 5 times with the prior upper bound for the number of clusters 604 
varying between 100 and 300. All runs converged to the same estimate of the global posterior 605 
mode partition, indicating a strong support for the obtained clustering solution. Phylogenetic 606 
trees were generated using SNP sites determined by SNP-sites from the core genome 607 
alignments, or from SNPs identified by mapping to reference genomes, using RAxML 7.8.6 608 
with 100 bootstraps (Stamatakis 2006). For the reference-based SNP tree the sequences were 609 
mapped against a selected reference genome using SMALT and SNPs were called using 610 
SAMtools (Li et al. 2009; Ponstingl 2013). Reference genomes used in the analyses were 611 
CFT073 (AE014075.1) and EC958 (NZ_HG941718.1) (Forde et al. 2014), for ST73 and 612 
ST131, respectively Phage sequences were recognized using Phast (Zhou et al. 2011) and 613 
were masked from the analysis. Phast results can be retrieved from the program website 614 
(phast.wishartlab.com). Gubbins with default settings was used to identify recombination 615 
(Croucher et al. 2015), and the regions detected were masked from the alignment. The 616 
resulting alignment was used to produce a phylogenetic tree with RAxML.  617 
 618 
Temporal analysis of ST69 and ST131 was performed with BEAST 1.7.5.1-1 (Drummond 619 
and Rambaut 2007; Drummond et al. 2012) on a reference-based alignment of 50 randomly 620 
selected isolates from both STs. This approach was used since BEAST did not converge with 621 
the complete collections or 100 isolates in the available running time on the computer cluster. 622 
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References in the analysis were UMN026 (NC_011751.1) and EC958 (NZ_HG941718.1), for 623 
ST69 and ST131, respectively. Phast was used to identify phage regions and Gubbins was 624 
used to identify regions of recombination in the alignment and these regions were masked 625 
from the alignment before running BEAST. The nucleotide substitution model used was 626 
GTRGAMMA and we ran three replicates of all combinations for strict clock and lognormal 627 
relaxed clock and three tree priors; coalescent: constant population, exponential growth and 628 
Bayesian skyline. To estimate what was the best fitting model for each ST we compared 629 
Bayes Factors from marginal likelihood estimations calculated by path and stepping-stone 630 
sampling (Baele et al. 2012; Baele et al. 2013). Only the models that converged well and had 631 
effective sample size (ESS) over 200 for each parameter were included in the test. The best 632 
fitting model was used in the subsequent analyses. For ST131 this was Bayesian skyline 633 
model under the log-normal relaxed clock and for ST69 it was constant population model 634 
under the strict clock followed by Bayesian skyline model under the strict clock. For the 635 
construction of the Bayesian skyline for ST69 we used data generated with Bayesian skyline 636 
model under the strict clock. The temporal analysis for ST131 was confirmed with Least-637 
Squares Dating (LSD, version 0.3beta) using all isolates (To et al. 2016). 638 
 639 
 640 
In silico PCR was used to assign isolates to E. coli phylogroups A, B1, B2, D, E and F using 641 
the Clermont method (Clermont et al. 2000; Clermont et al. 2013), to assign ST131 isolates 642 
to B, H30-R (C1) and H30-Rx (C2) clades (Price et al. 2013; Ben Zakour et al. 2016) and to 643 
perform plasmid incompatibility group/replicon typing (Carattoli et al. 2005). Primers 644 
designed to detect clade specific SNPs reported by Ben Zakour et al. are presented in 645 
Supplementary Table S3. In silico serotyping was performed with SRST2 according to the 646 
author’s instructions with the database provided (Ingle et al. 2015). Here, serotype is defined 647 
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by presence of known genes encoding serotype-determining enzymes. The results required 648 
minor manual curating when the gene typing resulted in discrepancy between the gene pairs 649 
defining the serotype. This occurred mostly with the novel sequences the authors had 650 
included in the database based on their own results. Antibiotic resistance genes were detected 651 
using SRST2 with 98% identity. An in-house curated database based on ResFinder of 652 
antibiotic resistance genes was used as reference (Zankari et al. 2012). Parsimony 653 
reconstruction of the presence of blaCTX-M-15 in ST131 was performed with Fitch algorithm 654 
(Fitch 1971). Virulence genes were analysed with SRST2 using the database and protocols 655 
described by the authors and using an Escherichia genus-specific database clustering together 656 
genes with 90% similarity and detecting genes with 90% identity and at least 90% coverage 657 
(Inouye et al. 2014). Gene typing for gyrA, parC and fimH was performed by clustering 658 
sequences acquired from Roary using Usearch (Edgar 2010). Clustering was based on 659 
reference sequences for seven fimH genes, seven gyrA genes and ten parC genes. The alleles 660 
tested were as described previously (Johnson et al. 2013) with the following exceptions: 661 
fimH15 was omitted and fimH31 was added to the analysis (Johnson et al. 2013). 662 
 663 
Statistical testing 664 
To test if a specific gene is more often found in certain STs, we used Pearson's chi-squared 665 
test statistic using prop.test in R (R Core Team 2015). 666 
 667 
DATA ACCESS 668 
Sequence reads have been submitted to the European Nucleotide Archive (ENA) 669 
(www.ebi.ac.uk/ena) under the accession numbers listed in Supplemental Data S1. The lists 670 
of genes present in the core genome and core genome alignment can be downloaded from 671 
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Figshare (https://figshare.com/s/20dfe5842f952497619b and 672 
https://figshare.com/s/3a12b011ff3c291a271b). 673 
 674 
ACKNOWLEDGEMENTS 675 
We thank Beth Blane for laboratory assistance, and the library construction, sequencing and 676 
core informatics teams at the Wellcome Trust Sanger Institute. We thank the BSAC for 677 
providing isolates from the BSAC Resistance Surveillance Project. This publication presents 678 
independent research supported by the Health Innovation Challenge Fund (HICF-T5-342 and 679 
WT098600), a parallel funding partnership between the UK Department of Health and 680 
Wellcome Trust. The views expressed in this publication are those of the authors and not 681 
necessarily those of the Department of Health, Public Health England or the Wellcome Trust. 682 
 683 
DISCLOSURE DECLARATION 684 
The authors report no conflicts of interest. 685 
  686 
  687 
 36 
References 688 
 689 
Adams-Sapper S, Diep BA, Perdreau-Remington F, Riley LW. 2013. Clonal composition and 690 
community clustering of drug-susceptible and -resistant Escherichia coli isolates from 691 
bloodstream infections. Antimicrob Agents Chemother 57(1): 490-497. 692 
Alhashash F, Wang X, Paszkiewicz K, Diggle M, Zong Z, McNally A. 2016. Increase in 693 
bacteraemia cases in the East Midlands region of the UK due to MDR Escherichia 694 
coli ST73: high levels of genomic and plasmid diversity in causative isolates. J 695 
Antimicrob Chemother 71(2): 339-343. 696 
Alhashash F, Weston V, Diggle M, McNally A. 2013. Multidrug-resistant Escherichia coli 697 
bacteremia. Emerg Infect Dis 19(10): 1699-1701. 698 
Allsopp LP, Beloin C, Moriel DG, Totsika M, Ghigo JM, Schembri MA. 2012. Functional 699 
heterogeneity of the UpaH autotransporter protein from uropathogenic Escherichia 700 
coli. J Bacteriol 194(21): 5769-5782. 701 
Allsopp LP, Totsika M, Tree JJ, Ulett GC, Mabbett AN, Wells TJ, Kobe B, Beatson SA, 702 
Schembri MA. 2010. UpaH is a newly identified autotransporter protein that 703 
contributes to biofilm formation and bladder colonization by uropathogenic 704 
Escherichia coli CFT073. Infect Immun 78(4): 1659-1669. 705 
Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob 706 
Chemother 48 Suppl 1: 5-16. 707 
Baele G, Lemey P, Bedford T, Rambaut A, Suchard MA, Alekseyenko AV. 2012. Improving 708 
the accuracy of demographic and molecular clock model comparison while 709 
accommodating phylogenetic uncertainty. Mol Biol Evol 29(9): 2157-2167. 710 
Baele G, Li WL, Drummond AJ, Suchard MA, Lemey P. 2013. Accurate model selection of 711 
relaxed molecular clocks in bayesian phylogenetics. Mol Biol Evol 30(2): 239-243. 712 
Banerjee R, Johnston B, Lohse C, Chattopadhyay S, Tchesnokova V, Sokurenko EV, 713 
Johnson JR. 2013. The clonal distribution and diversity of extraintestinal Escherichia 714 
coli isolates vary according to patient characteristics. Antimicrob Agents Chemother 715 
57(12): 5912-5917. 716 
Ben Zakour NL, Alsheikh-Hussain AS, Ashcroft MM, Khanh Nhu NT, Roberts LW, Stanton-717 
Cook M, Schembri MA, Beatson SA. 2016. Sequential Acquisition of Virulence and 718 
Fluoroquinolone Resistance Has Shaped the Evolution of Escherichia coli ST131. 719 
MBio 7(2): e00347-00316. 720 
Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. 2011. Scaffolding pre-assembled 721 
contigs using SSPACE. Bioinformatics 27(4): 578-579. 722 
Boetzer M, Pirovano W. 2012. Toward almost closed genomes with GapFiller. Genome Biol 723 
13(6): R56. 724 
Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of 725 
plasmids by PCR-based replicon typing. J Microbiol Methods 63(3): 219-228. 726 
Chatzidaki-Livanis M, Geva-Zatorsky N, Comstock LE. 2016. Bacteroides fragilis type VI 727 
secretion systems use novel effector and immunity proteins to antagonize human gut 728 
Bacteroidales species. Proc Natl Acad Sci U S A 113(13): 3627-3632. 729 
Chen L, Hu H, Chavda KD, Zhao S, Liu R, Liang H, Zhang W, Wang X, Jacobs MR, 730 
Bonomo RA et al. 2014. Complete sequence of a KPC-producing IncN multidrug-731 
resistant plasmid from an epidemic Escherichia coli sequence type 131 strain in 732 
China. Antimicrob Agents Chemother 58(4): 2422-2425. 733 
Chen SL, Hung CS, Xu J, Reigstad CS, Magrini V, Sabo A, Blasiar D, Bieri T, Meyer RR, 734 
Ozersky P et al. 2006. Identification of genes subject to positive selection in 735 
uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc 736 
Natl Acad Sci U S A 103(15): 5977-5982. 737 
 37 
Cheng L, Connor TR, Siren J, Aanensen DM, Corander J. 2013. Hierarchical and spatially 738 
explicit clustering of DNA sequences with BAPS software. Mol Biol Evol 30(5): 739 
1224-1228. 740 
Clark G, Paszkiewicz K, Hale J, Weston V, Constantinidou C, Penn C, Achtman M, McNally 741 
A. 2012. Genomic analysis uncovers a phenotypically diverse but genetically 742 
homogeneous Escherichia coli ST131 clone circulating in unrelated urinary tract 743 
infections. J Antimicrob Chemother 67(4): 868-877. 744 
Clermont O, Bonacorsi S, Bingen E. 2000. Rapid and simple determination of the 745 
Escherichia coli phylogenetic group. Appl Environ Microbiol 66(10): 4555-4558. 746 
Clermont O, Christenson JK, Denamur E, Gordon DM. 2013. The Clermont Escherichia coli 747 
phylo-typing method revisited: improvement of specificity and detection of new 748 
phylo-groups. Environ Microbiol Rep 5(1): 58-65. 749 
Corander J, Marttinen P, Siren J, Tang J. 2008. Enhanced Bayesian modelling in BAPS 750 
software for learning genetic structures of populations. BMC Bioinformatics 9: 539. 751 
Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris 752 
SR. 2015. Rapid phylogenetic analysis of large samples of recombinant bacterial 753 
whole genome sequences using Gubbins. Nucleic Acids Res 43(3): e15. 754 
Day MJ, Doumith M, Abernethy J, Hope R, Reynolds R, Wain J, Livermore DM, Woodford 755 
N. 2016. Population structure of Escherichia coli causing bacteraemia in the UK and 756 
Ireland between 2001 and 2010. J Antimicrob Chemother 71(8): 2139-2142. 757 
de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. 2013. The 758 
changing epidemiology of bacteraemias in Europe: trends from the European 759 
Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 19(9): 860-868. 760 
Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling 761 
trees. BMC Evol Biol 7: 214. 762 
Drummond AJ, Suchard MA, Xie D, Rambaut A. 2012. Bayesian phylogenetics with 763 
BEAUti and the BEAST 1.7. Mol Biol Evol 29(8): 1969-1973. 764 
Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. 765 
Bioinformatics 26(19): 2460-2461. 766 
Elixhauser A, Friedman B, Stranges E. 2011. Septicemia in U.S. Hospitals, 2009: Statistical 767 
Brief #122. In Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, 768 
Rockville (MD). 769 
ESPAUR. 2015. English surveillance programme for antimicrobial utilisation and resistance 770 
(ESPAUR) 2010 to 2014: report 2015. Public Health England. 771 
Fitch WM. 1971. Toward Defining Course of Evolution - Minimum Change for a Specific 772 
Tree Topology. Systematic Zoology 20(4): 406-416. 773 
Forde BM, Ben Zakour NL, Stanton-Cook M, Phan MD, Totsika M, Peters KM, Chan KG, 774 
Schembri MA, Upton M, Beatson SA. 2014. The complete genome sequence of 775 
Escherichia coli EC958: a high quality reference sequence for the globally 776 
disseminated multidrug resistant E. coli O25b:H4-ST131 clone. PLoS One 9(8): 777 
e104400. 778 
Gerver R, Mihalkova M, Abernethy J, Bou-Antoun S, Nsonwu O, Kausar S, Wasti S, Apraku 779 
D, Davies J, Hope R. 2015. Annual Epidemiological Commentary: Mandatory 780 
MRSA, MSSA and E. coli bacteraemia and C. difficile infection data, 2014/15. p. 81. 781 
Publich Health England, London, United Kingdom. 782 
Gibreel TM, Dodgson AR, Cheesbrough J, Fox AJ, Bolton FJ, Upton M. 2012. Population 783 
structure, virulence potential and antibiotic susceptibility of uropathogenic 784 
Escherichia coli from Northwest England. J Antimicrob Chemother 67(2): 346-356. 785 
 38 
Guyer DM, Henderson IR, Nataro JP, Mobley HL. 2000. Identification of sat, an 786 
autotransporter toxin produced by uropathogenic Escherichia coli. Mol Microbiol 787 
38(1): 53-66. 788 
Hazen TH, Donnenberg MS, Panchalingam S, Antonio M, Hossain A, Mandomando I, 789 
Ochieng JB, Ramamurthy T, Tamboura B, Qureshi S et al. 2016. Genomic diversity 790 
of EPEC associated with clinical presentations of differing severity. Nature 791 
Microbiology 1: 15014. 792 
Horner C, Fawley W, Morris K, Parnell P, Denton M, Wilcox M. 2014. Escherichia coli 793 
bacteraemia: 2 years of prospective regional surveillance (2010-12). J Antimicrob 794 
Chemother 69(1): 91-100. 795 
Ingle D, Valcanis M, Kuzevski A, Tauschek M, Inouye M, Stinear T, Levine MM, Robins-796 
Browne RM, Holt KE. 2015. EcOH: In silico serotyping of E. coli from short read 797 
data. bioRxiv: http://dx.doi.org/10.1101/032151. 798 
Ingle DJ, Tauschek M, Edwards DJ, Hocking DM, Pickard DJ, Azzopardi KI, Amarasena T, 799 
Bennett-Wood V, Pearson JS, Tamboura B et al. 2016. Evolution of atypical 800 
enteropathogenic E. coli by repeated acquisition of LEE pathogenicity island variants. 801 
Nature Microbiology 1: 15010. 802 
Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J, Holt KE. 2014. 803 
SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. 804 
Genome Med 6(11): 90. 805 
Ironmonger D, Edeghere O, Bains A, Loy R, Woodford N, Hawkey PM. 2015. Surveillance 806 
of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million 807 
over 4 years. J Antimicrob Chemother 70(6): 1744-1750. 808 
Johnson JR, Delavari P, Kuskowski M, Stell AL. 2001. Phylogenetic distribution of 809 
extraintestinal virulence-associated traits in Escherichia coli. J Infect Dis 183(1): 78-810 
88. 811 
Johnson JR, Stell AL. 2000. Extended virulence genotypes of Escherichia coli strains from 812 
patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 813 
181(1): 261-272. 814 
Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers 815 
P, Qin X, Butler-Wu S et al. 2013. Abrupt emergence of a single dominant multidrug-816 
resistant strain of Escherichia coli. J Infect Dis 207(6): 919-928. 817 
Lecointre G, Rachdi L, Darlu P, Denamur E. 1998. Escherichia coli molecular phylogeny 818 
using the incongruence length difference test. Mol Biol Evol 15(12): 1685-1695. 819 
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin 820 
R, Genome Project Data Processing S. 2009. The Sequence Alignment/Map format 821 
and SAMtools. Bioinformatics 25(16): 2078-2079. 822 
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X 823 
et al. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in 824 
animals and human beings in China: a microbiological and molecular biological 825 
study. Lancet Infect Dis 16(2): 161-168. 826 
Mellies JL, Navarro-Garcia F, Okeke I, Frederickson J, Nataro JP, Kaper JB. 2001. espC 827 
pathogenicity island of enteropathogenic Escherichia coli encodes an enterotoxin. 828 
Infect Immun 69(1): 315-324. 829 
Miajlovic H, Mac Aogain M, Collins CJ, Rogers TR, Smith SG. 2016. Characterization of 830 
Escherichia coli bloodstream isolates associated with mortality. J Med Microbiol 831 
65(1): 71-79. 832 
Nicolas-Chanoine MH, Bertrand X, Madec JY. 2014. Escherichia coli ST131, an intriguing 833 
clonal group. Clin Microbiol Rev 27(3): 543-574. 834 
 39 
Olesen B, Frimodt-Moller J, Leihof RF, Struve C, Johnston B, Hansen DS, Scheutz F, 835 
Krogfelt KA, Kuskowski MA, Clabots C et al. 2014. Temporal Trends in 836 
Antimicrobial Resistance and Virulence-associated Traits within Escherichia coli 837 
Sequence Type 131 Clonal Group and its H30 and H30-Rx Subclones, 1968 - 2011. 838 
Antimicrob Agents Chemother 58(11): 6886-6895. 839 
Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Falush D, 840 
Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. 841 
Bioinformatics 31(22): 3691-3693. 842 
Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, Harris SR. 2016. SNP-sites: 843 
rapid efficient extraction of SNPs from multi-FASTA alignments. Microbial 844 
Genomics 2(4): doi:10.1099/mgen.1090.000056. 845 
Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, Phan 846 
MD, Gomes Moriel D, Peters KM, Davies M et al. 2014. Global dissemination of a 847 
multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111(15): 5694-848 
5699. 849 
Picard B, Garcia JS, Gouriou S, Duriez P, Brahimi N, Bingen E, Elion J, Denamur E. 1999. 850 
The link between phylogeny and virulence in Escherichia coli extraintestinal 851 
infection. Infect Immun 67(2): 546-553. 852 
Ponstingl H. 2013. SMALT 0.7.5. http://www.sanger.ac.uk/resources/software/smalt/. 853 
Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig 854 
M, Chattopadhyay S, Stegger M et al. 2013. The epidemic of extended-spectrum-855 
beta-lactamase-producing Escherichia coli ST131 is driven by a single highly 856 
pathogenic subclone, H30-Rx. MBio 4(6): e00377-00313. 857 
R Core Team. 2015. R: A Language and Environment for Statistical Computing. R 858 
Foundation for Statistical Computing, Vienna, Austria. 859 
Rasko DA, Rosovitz MJ, Myers GS, Mongodin EF, Fricke WF, Gajer P, Crabtree J, Sebaihia 860 
M, Thomson NR, Chaudhuri R et al. 2008. The pangenome structure of Escherichia 861 
coli: comparative genomic analysis of E. coli commensal and pathogenic isolates. J 862 
Bacteriol 190(20): 6881-6893. 863 
Reynolds R, Hope R, Williams L, Surveillance BWPoR. 2008. Survey, laboratory and 864 
statistical methods for the BSAC Resistance Surveillance Programmes. J Antimicrob 865 
Chemother 62 Suppl 2: ii15-28. 866 
Salipante SJ, Roach DJ, Kitzman JO, Snyder MW, Stackhouse B, Butler-Wu SM, Lee C, 867 
Cookson BT, Shendure J. 2015. Large-scale genomic sequencing of extraintestinal 868 
pathogenic Escherichia coli strains. Genome Res 25(1): 119-128. 869 
Sana TG, Flaugnatti N, Lugo KA, Lam LH, Jacobson A, Baylot V, Durand E, Journet L, 870 
Cascales E, Monack DM. 2016. Salmonella Typhimurium utilizes a T6SS-mediated 871 
antibacterial weapon to establish in the host gut. Proc Natl Acad Sci U S A 113(34): 872 
E5044-5051. 873 
Schmidt H, Hensel M. 2004. Pathogenicity islands in bacterial pathogenesis. Clin Microbiol 874 
Rev 17(1): 14-56. 875 
Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30(14): 876 
2068-2069. 877 
Serapio-Palacios A, Navarro-Garcia F. 2016. EspC, an Autotransporter Protein Secreted by 878 
Enteropathogenic Escherichia coli, Causes Apoptosis and Necrosis through Caspase 879 
and Calpain Activation, Including Direct Procaspase-3 Cleavage. MBio 7(3): e00479-880 
00416. 881 
Skov RL, Monnet DL. 2016. Plasmid-mediated colistin resistance (mcr-1 gene): three months 882 
later, the story unfolds. Euro Surveill 21(9). 883 
 40 
Stamatakis A. 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses 884 
with thousands of taxa and mixed models. Bioinformatics 22(21): 2688-2690. 885 
Stein M, Kenny B, Stein MA, Finlay BB. 1996. Characterization of EspC, a 110-kilodalton 886 
protein secreted by enteropathogenic Escherichia coli which is homologous to 887 
members of the immunoglobulin A protease-like family of secreted proteins. J 888 
Bacteriol 178(22): 6546-6554. 889 
Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE, Sebra R, Turner P, Anson 890 
LW, Kasarskis A, Batty EM et al. 2016. Evolutionary History of the Global 891 
Emergence of the Escherichia coli Epidemic Clone ST131. MBio 7(2): e02162-02115. 892 
Tan A, Petty NK, Hocking D, Bennett-Wood V, Wakefield M, Praszkier J, Tauschek M, 893 
Yang J, Robins-Browne R. 2015. Evolutionary adaptation of an AraC-like regulatory 894 
protein in Citrobacter rodentium and Escherichia species. Infect Immun 83(4): 1384-895 
1395. 896 
To TH, Jung M, Lycett S, Gascuel O. 2016. Fast Dating Using Least-Squares Criteria and 897 
Algorithms. Syst Biol 65(1): 82-97. 898 
Totsika M, Beatson SA, Sarkar S, Phan MD, Petty NK, Bachmann N, Szubert M, Sidjabat 899 
HE, Paterson DL, Upton M et al. 2011. Insights into a multidrug resistant Escherichia 900 
coli pathogen of the globally disseminated ST131 lineage: genome analysis and 901 
virulence mechanisms. PLoS One 6(10): e26578. 902 
von Mentzer A, Connor TR, Wieler LH, Semmler T, Iguchi A, Thomson NR, Rasko DA, 903 
Joffre E, Corander J, Pickard D et al. 2014. Identification of enterotoxigenic 904 
Escherichia coli (ETEC) clades with long-term global distribution. Nat Genet 46(12): 905 
1321-1326. 906 
Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MC, 907 
Ochman H et al. 2006. Sex and virulence in Escherichia coli: an evolutionary 908 
perspective. Mol Microbiol 60(5): 1136-1151. 909 
Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, 910 
Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J 911 
Antimicrob Chemother 67(11): 2640-2644. 912 
Zerbino DR, Birney E. 2008. Velvet: algorithms for de novo short read assembly using de 913 
Bruijn graphs. Genome Res 18(5): 821-829. 914 
Zhang C, Xu X, Pu S, Huang S, Sun J, Yang S, Zhang L. 2014. Characterization of 915 
carbapenemases, extended spectrum beta-lactamases, quinolone resistance and 916 
aminoglycoside resistance determinants in carbapenem-non-susceptible Escherichia 917 
coli from a teaching hospital in Chongqing, Southwest China. Infect Genet Evol 27: 918 
271-276. 919 
Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST: a fast phage search tool. 920 
Nucleic Acids Res 39(Web Server issue): W347-352. 921 
 922 
923 
 41 
 Table 1. Proportion of antibiotic non-susceptible isolates in each year. 924 
    2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Aminoglycosides             
 Gentamicin 10.5 5.7 2.8 4.6 7.5 11.7 12.7 12.1 4.1 7.2 9.4 5.0 
 Amikacin      0.0 3.8 7.0 5.6 3.0 1.4 3.0 
  Tobramycin           0.0 15.4 10.5 9.7 7.6 12.7 8.9 
               
Antifolates                         
  Trimethopri
m 
          50.0 42.3 31.6 34.7 28.8 33.8 36.6 
               
Beta-lactams                         
Extended spectrum 
penicillins 
                        
 Amoxicillin 55.3 58.5 63.0 46.8 59.8 66.4 62.2 71.0 65.0 63.2 53.0   
  Ampicillin           50.0 59.6 50.9 56.9 54.5 63.4 65.3 
               
Carbapenems                         
 Imipenem 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0   
 42 
 Ertapenem      0.0 0.0 0.0 1.4 0.0 0.0 0.0 
  Meropenem           0.0 0.0 0.0 0.0 0.0 0.0 0.0 
               
Monobactams                         
  Aztreonam           0.0 0.0 8.8 9.7 3.0 9.9 8.9 
               
1st & 2nd generation 
cephalosporins 
                        
 Cefalotin           75.0 63.5 49.1 47.2 50.0 53.5 59.4 
 Cefuroxime 13.2 10.4 8.3 14.7 15.0 20.7 15.3 22.3 22.7 14.4 13.5 13.9 
 Cefoxitin           25.0 5.8 5.3 8.3 9.1 5.6 5.9 
  Cefuroxime
Axetil 
          25.0 11.5 17.5 20.8 12.1 14.1 13.9 
               
3rd & 4th generation 
cephalosporins 
                        
 Ceftazidime 0.0 4.7 2.8 3.7 10.3 12.6 8.0 10.8 8.7 2.6 9.9 9.9 
 Cefotaxime  3.8 2.8 6.4 9.3 13.5 9.3 13.4 7.0 3.9 11.1 8.9 
  Cefepime           0.0 7.7 7.0 1.4 3.0 7.0 5.0 
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Quinolones                         
  Ciprofloxaci
n 
10.5 8.5 12.0 21.1 16.8 28.8 26.7 19.7 15.7 17.0 19.9 17.8 
               
Tetracyclines                         
  Tigecycline   0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 1.0 
               
Combinations                         
 AmoxiClav* 19.7 27.4 27.8 21.1 29.0 42.3 30.0 33.1 36.6 28.1 26.9 27.7 
  PipTaz** 6.6 9.4 9.3 27.5 4.7 19.8 4.7 12.1 9.4 6.5 2.3 7.1 
*Amoxicilline clavulanic acid            
**Piperacillin tazobactam            
NA=no information/not tested            
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